Washington: Mayo Clinic researchers have found a potential drug therapy for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD).The medication, tolvaptan, slowed the pace of kidney cyst growth over the three years of the study.The multicenter study found tolvaptan demonstrated a nearly 50 percent reduction in the rate of increase in total kidney volume (a measurement of kidney cyst growth) in ADPKD patients over the study period, compared to placebo.“ADPKD is the most common inherited and the fourth most common overall cause of kidney failure worldwide,” said lead author Vicente Torres, M.D., Ph.D., Mayo Clinic nephrologist.“In most patients with this disease, relentless cyst growth within the kidneys destroys the tissue, causes hypertension and painful complications, and negatively impacts the quality of life.
Azam Khan calls Modi a Fascist
Don`t rush with the Lokpal :BJP
CBI questions Madhu Koda on Coalgate
Stop govt from appointing new Army chief: BJP to Election Commission